MCID: RTN022
MIFTS: 52

Retinal Vein Occlusion

Categories: Cardiovascular diseases, Eye diseases, Rare diseases

Aliases & Classifications for Retinal Vein Occlusion

MalaCards integrated aliases for Retinal Vein Occlusion:

Name: Retinal Vein Occlusion 12 54 43 15 37 17 71
Occlusion, of Retinal Vein 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1727
MeSH 43 D012170
NCIt 49 C34981
SNOMED-CT 67 46085004
UMLS 71 C0035328

Summaries for Retinal Vein Occlusion

MalaCards based summary : Retinal Vein Occlusion, also known as occlusion, of retinal vein, is related to central retinal vein occlusion and macular retinal edema. An important gene associated with Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 709)
# Related Disease Score Top Affiliating Genes
1 central retinal vein occlusion 33.6 VEGFA SERPINF1 SERPINC1 MTHFR LOXL1 IL6
2 macular retinal edema 31.5 VEGFA SERPINF1 KDR IL6 CXCL8 CCL2
3 neovascular glaucoma 31.5 VEGFA KDR CXCL8
4 vasculitis 31.3 IL6 CD40LG CCL2 APOH
5 retinal detachment 31.3 VEGFA SERPINF1 IL6 CXCL8 CCL2
6 diabetic macular edema 31.2 VEGFA SERPINF1 IL6 CCL2
7 endophthalmitis 31.2 VEGFA IL6 CXCL8
8 branch retinal artery occlusion 31.2 VEGFA SERPINC1 MTHFR F3 F2
9 central retinal artery occlusion 31.1 VEGFA SERPINC1 F2 CD40LG
10 intraocular pressure quantitative trait locus 31.1 VEGFA SERPINF1 LOXL1 EDN1
11 homocysteinemia 31.0 SERPINE1 SERPINC1 MTHFR F5 F2 CCL2
12 lipid metabolism disorder 30.9 SERPINE1 IL6 CCL2 ACE
13 macular dystrophy, dominant cystoid 30.9 VEGFA SERPINF1 CXCL12 ACE
14 retinal vasculitis 30.9 CD40LG CCL2 APOH ACE
15 uveitis 30.9 SERPINF1 IL6 CXCL8 CCL2
16 prothrombin-related thrombophilia 30.8 MTHFR F2
17 neuroretinitis 30.7 CD40LG ACE
18 factor xii deficiency 30.7 SERPINC1 F5 F3 APOH
19 thrombophilia due to thrombin defect 30.7 SERPINE1 SERPINC1 MTHFR F5 F3 F2
20 homocystinuria 30.7 SERPINC1 MTHFR F5
21 macroglobulinemia 30.7 IL6 CXCL12 CD40LG
22 chorioretinitis 30.6 VEGFA IL6 CD40LG ACE
23 thrombophilia due to activated protein c resistance 30.6 SERPINE1 SERPINC1 MTHFR F5 F3 F2
24 amaurosis fugax 30.6 SERPINE1 MTHFR F5
25 thrombocytosis 30.6 SERPINC1 IL6 F3 F2
26 cryoglobulinemia 30.6 IL6 CD40LG APOH
27 thrombophilia 30.6 SERPINE1 SERPINC1 MTHFR F5 F3 F2
28 thrombotic thrombocytopenic purpura 30.6 SERPINC1 F3 CD40LG APOH
29 sticky platelet syndrome 30.6 SERPINE1 SERPINC1 F5
30 panuveitis 30.5 VEGFA IL6 CD40LG ACE
31 arteritic anterior ischemic optic neuropathy 30.5 MTHFR F5 F2 ACE
32 macular holes 30.5 VEGFA SERPINF1 CXCL8 CCL2 ANGPT2
33 compartment syndrome 30.5 SERPINC1 IL6 F3 F2
34 iritis 30.5 IL6 CD40LG ACE
35 iridocyclitis 30.5 IL6 CD40LG ACE
36 cavernous sinus thrombosis 30.5 SERPINC1 F2
37 carotid stenosis 30.5 VEGFA MTHFR CXCL8 ACE
38 conjunctivitis 30.4 IL6 CXCL8 CCL2
39 prothrombin deficiency, congenital 30.4 SERPINC1 F5 F2 APOH
40 von willebrand's disease 30.4 F5 F3 F2
41 sneddon syndrome 30.4 SERPINC1 F5 F2 APOH
42 neuritis 30.4 IL6 CXCL8 CCL2
43 microvascular complications of diabetes 5 30.3 VEGFA SERPINF1 SERPINE1 KDR CXCL12 ANGPT2
44 mixed connective tissue disease 30.3 IL6 CD40LG APOH
45 optic nerve disease 30.3 VEGFA IL6 EDN1 CD40LG ACE
46 protein s deficiency 30.3 SERPINE1 SERPINC1 MTHFR F5 F3 F2
47 transient cerebral ischemia 30.3 MTHFR CCL2 APOH
48 carotid artery disease 30.3 F3 CCL2 ACE
49 hemophilia b 30.3 SERPINC1 F3 F2
50 antiphospholipid syndrome 30.2 SERPINE1 SERPINC1 MTHFR F5 F3 F2

Graphical network of the top 20 diseases related to Retinal Vein Occlusion:



Diseases related to Retinal Vein Occlusion

Symptoms & Phenotypes for Retinal Vein Occlusion

MGI Mouse Phenotypes related to Retinal Vein Occlusion:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ACE ANGPT2 CD40LG CXCL12 EDN1 F2
2 homeostasis/metabolism MP:0005376 10.34 ACE ANGPT2 APOH CD40LG EDN1 F2
3 hematopoietic system MP:0005397 10.23 ACE CD40LG CXCL12 F2 F3 IL6
4 immune system MP:0005387 10.22 ACE ANGPT2 CCL2 CD40LG CXCL12 F2
5 mortality/aging MP:0010768 10.16 ACE ANGPT2 APOH CD40LG CXCL12 EDN1
6 integument MP:0010771 10.11 ANGPT2 CD40LG F2 F3 F5 IL6
7 nervous system MP:0003631 10 CD40LG CXCL12 EDN1 F2 F3 F5
8 liver/biliary system MP:0005370 9.97 ACE CXCL12 F5 IL6 KDR MTHFR
9 reproductive system MP:0005389 9.65 ACE CD40LG CXCL12 F2 IL6 LOXL1
10 respiratory system MP:0005388 9.23 ANGPT2 F2 F3 IL6 KDR LOXL1

Drugs & Therapeutics for Retinal Vein Occlusion

Drugs for Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
Povidone-iodine Approved Phase 4 25655-41-8
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Dipivefrin Approved Phase 4 52365-63-6 3105
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Ranibizumab Approved Phase 4 347396-82-1 459903
11
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
12 Antineoplastic Agents, Immunological Phase 4
13 Immunosuppressive Agents Phase 4
14 Immunologic Factors Phase 4
15 Triamcinolone diacetate Phase 4
16 Triamcinolone hexacetonide Phase 4
17 triamcinolone acetonide Phase 4
18 Mitogens Phase 4
19 Endothelial Growth Factors Phase 4
20 Pharmaceutical Solutions Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Anti-Bacterial Agents Phase 4
23 Dexamethasone 21-phosphate Phase 4
24 Mitomycins Phase 4
25 Dermatologic Agents Phase 4
26 Photosensitizing Agents Phase 4
27 Analgesics Phase 4
28 Analgesics, Non-Narcotic Phase 4
29 Antirheumatic Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Cathartics Phase 4
32 Lubricant Eye Drops Phase 4
33 Laxatives Phase 4
34 Carboxymethylcellulose Sodium Phase 4
35 Angiogenesis Inhibitors Phase 4
36 Antiemetics Phase 4
37 HIV Protease Inhibitors Phase 4
38 Anti-Inflammatory Agents Phase 4
39 Gastrointestinal Agents Phase 4
40
protease inhibitors Phase 4
41 BB 1101 Phase 4
42 glucocorticoids Phase 4
43 Antineoplastic Agents, Hormonal Phase 4
44 Hormone Antagonists Phase 4
45 Autonomic Agents Phase 4
46 Hormones Phase 4
47
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
48
Atorvastatin Approved Phase 3 134523-00-5 60823
49
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
50
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782

Interventional clinical trials:

(show top 50) (show all 266)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
2 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
3 Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
4 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
5 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
6 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
7 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
8 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4 dexamethasone intravitreal implant
9 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
10 Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis Completed NCT01448018 Phase 4 ranibizumab
11 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
12 Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
13 A 6-Month, Single Site, Masked, Randomized,Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4 Avastin;Osurdex;Avastin
14 Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion. Completed NCT02478515 Phase 4 Ranibizumab
15 An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18) Completed NCT01580020 Phase 4 Dexamethasone
16 Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO) Completed NCT01027481 Phase 4 Lucentis
17 A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Completed NCT02953938 Phase 4
18 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
19 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
20 A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months. Completed NCT01710839 Phase 4 0.5mg Ranibizumab
21 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
22 A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
23 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
24 A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium. Completed NCT01573572 Phase 4 pegaptanib sodium injection
25 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
26 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
27 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
28 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
29 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
30 A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study) Recruiting NCT03908307 Phase 4 OZURDEX
31 Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO Recruiting NCT03892434 Phase 4 Intravitreal bevacizumab and dexamethasone implant Injection
32 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Recruiting NCT03405376 Phase 4 Intravitreal aflibercept injection
33 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study Recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
34 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study Recruiting NCT03056079 Phase 4 Intravitreal aflibercept
35 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
36 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Recruiting NCT03506750 Phase 4 IVC
37 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Enrolling by invitation NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
38 Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion: a Randomized and Controlled Clinical Study. Not yet recruiting NCT04062370 Phase 4 Ranibizumab
39 A Randomized Trial Comparing Treatment With Aflibercept and Ranibizuamab for Macular Edema After Branch Retinal Vein Occlusion Not yet recruiting NCT03709745 Phase 4 Aflibercept Injection [Eylea];Ranibizumab Injection [Lucentis]
40 Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity Terminated NCT01795209 Phase 4 Ranibizumab
41 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
42 A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion Unknown status NCT01189526 Phase 3 Ranibizumab
43 Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO) Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
44 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
45 Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients. Unknown status NCT03391219 Phase 2, Phase 3 injection bevacizumab;injection Combined Bevacizumab and Fasudil
46 Does Avastin Change Evolution in Juxtafoveal Telangiectasias? Unknown status NCT00406380 Phase 3 Bevacizumab
47 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study) Unknown status NCT01635803 Phase 2, Phase 3 Bevacizumab;Ranibizumab
48 Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion Unknown status NCT03353324 Phase 2, Phase 3 intravitreal injection of bevacizumab
49 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
50 A Randomized, Sham Controlled, Multicenter, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion Completed NCT01512901 Phase 2, Phase 3 Betamethasone Microsphere (DE-102) Low Dose;Betamethasone Microsphere (DE-102) High Dose;Sham

Search NIH Clinical Center for Retinal Vein Occlusion

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Vein Occlusion cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Vein Occlusion:
Bone marrow-derived hematopoietic stem cells for retinopathy
Embryonic/Adult Cultured Cells Related to Retinal Vein Occlusion:
Bone marrow-derived hematopoietic CD34+ progenitors PMIDs: 22247454
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22247454

Cochrane evidence based reviews: retinal vein occlusion

Genetic Tests for Retinal Vein Occlusion

Anatomical Context for Retinal Vein Occlusion

MalaCards organs/tissues related to Retinal Vein Occlusion:

40
Eye, Endothelial, Retina, Bone, Bone Marrow, Testes, Brain

Publications for Retinal Vein Occlusion

Articles related to Retinal Vein Occlusion:

(show top 50) (show all 4394)
# Title Authors PMID Year
1
Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series. 54 61
20429890 2010
2
Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. 54 61
19881397 2010
3
Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. 54 61
19744723 2009
4
The anti-angiogenic isoforms of VEGF in health and disease. 61 54
19909248 2009
5
[Retinal vein occlusion: anti-VEGF treatments]. 61 54
19879018 2009
6
Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. 61 54
19624346 2009
7
Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor. 61 54
18797821 2009
8
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. 61 54
19381089 2009
9
Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. 61 54
19278477 2008
10
Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. 54 61
18988180 2008
11
Visual prognosis and vitreous cytokine levels after arteriovenous sheathotomy in branch retinal vein occlusion associated with macular oedema. 54 61
18039346 2008
12
Retinal vascular occlusions: an interdisciplinary challenge. 61 54
19626196 2008
13
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. 61 54
18449423 2008
14
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. 61 54
18362932 2008
15
Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. 61 54
16826241 2008
16
Anticoagulant therapy after retinal vein occlusion in patients with protein S deficiency (Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. Vol. 42[4]). 54 61
18059510 2007
17
Thrombophilic mutations and risk of retinal vein occlusion. 61 54
18235909 2007
18
[Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. 61 54
17372737 2007
19
The deficiencies of protein C, protein S and antithrombin III in patients with retinal vein occlusion: a Turkish sample. 54 61
17105492 2006
20
Retinal vein occlusion associated with antithrombin deficiency secondary to a novel G9840C missense mutation. 61 54
16908819 2006
21
Recurrent branch retinal vein occlusion with factor V leiden mutation. 54 61
16113634 2006
22
[Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. 61 54
16763863 2006
23
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. 54 61
16133018 2006
24
[Recurrent incomplete central retinal vein occlusion in a patient with hereditary thrombophilia]. 61 54
16848214 2006
25
Antiphospholipid syndrome in patients with retinal venous occlusion. 61 54
16461072 2006
26
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. 54 61
16086947 2005
27
Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. 54 61
16113792 2005
28
Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo. 54 61
15111579 2004
29
Elevated erythropoietin in vitreous with ischemic retinal diseases. 54 61
15073535 2004
30
MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. 61 54
14994919 2003
31
Hyperhomocysteinemia in central retinal vein occlusion in young adults. 61 54
15513477 2003
32
Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. 54 61
12972759 2003
33
Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. 54 61
12877902 2003
34
High prevalence of resistance to APC in young patients with retinal vein occlusion. 61 54
11935272 2002
35
Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. 61 54
11820306 2001
36
No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. 61 54
11340395 2001
37
Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. 61 54
10634550 1999
38
Prevalence of factor V Leiden in patients with retinal vein occlusion. 61 54
10634553 1999
39
Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. 61 54
10634552 1999
40
Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. 61 54
10485556 1999
41
Diagnosis of activated protein C resistance in retinal vein occlusion. 61 54
9924393 1998
42
Bilateral retinal vein occlusion associated with factor V Leiden mutation. 61 54
9730185 1998
43
Factor V Leiden, activated protein C resistance, and retinal vein occlusion. 61 54
9730172 1998
44
Bilateral retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation. 61 54
9402832 1997
45
Prevalence of factor V Leiden in young adults with retinal vein occlusion. 61 54
9031476 1997
46
Activated protein C and retinal vein occlusion. 61 54
8703852 1996
47
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 61 54
7540233 1995
48
[Retinal vein occlusion and resistance to activated protein C]. 61 54
8745708 1995
49
Normal activities of protein C, protein S and antithrombin III in young patients with retinal vein occlusion. 54 61
2151449 1990
50
Comment on: Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
31733688 2020

Variations for Retinal Vein Occlusion

Expression for Retinal Vein Occlusion

Search GEO for disease gene expression data for Retinal Vein Occlusion.

Pathways for Retinal Vein Occlusion

Pathways related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 SERPINF1 KDR IL6 F2 EDN1 CXCL8
2
Show member pathways
13.48 VEGFA KDR IL6 F2 CXCL8 CXCL12
3
Show member pathways
13.24 KDR IL6 CXCL8 CXCL12 CD40LG CCL2
4
Show member pathways
13.23 VEGFA SERPINE1 SERPINC1 F5 F3 F2
5
Show member pathways
12.99 KDR IL6 F2 CXCL12 CCL2 ACE
6
Show member pathways
12.88 VEGFA IL6 CXCL8 CXCL12 CCL2 ANGPT2
7
Show member pathways
12.79 VEGFA IL6 CXCL8 CXCL12 CD40LG
8 12.79 VEGFA IL6 F2 EDN1 CXCL8 CXCL12
9
Show member pathways
12.27 IL6 CXCL8 CXCL12 CCL2
10
Show member pathways
12.25 SERPINE1 MTHFR IL6 F2 CCL2
11
Show member pathways
12.15 SERPINE1 IL6 F3 EDN1 CXCL8
12 12.05 VEGFA KDR EDN1 CCL2
13
Show member pathways
12 SERPINE1 SERPINC1 F5 F3 F2
14 11.93 SERPINE1 SERPINC1 F5 F3 F2
15 11.92 VEGFA IL6 CXCL8 CCL2
16 11.79 KDR F3 CCL2 ANGPT2
17 11.61 VEGFA SERPINE1 EDN1 CXCL12
18 11.59 VEGFA SERPINE1 IL6 EDN1 ANGPT2
19
Show member pathways
11.58 VEGFA IL6 CXCL8 CD40LG
20 11.56 IL6 EDN1 CXCL8 CCL2
21 11.51 VEGFA IL6 CXCL8
22 11.48 IL6 CXCL8 CCL2
23 11.32 IL6 CXCL8 CD40LG CCL2
24 11.32 VEGFA IL6 CXCL8 CXCL12 CCL2
25 11.31 IL6 CXCL8 CCL2
26 11.3 VEGFA SERPINE1 KDR
27 11.26 CD40LG CCL2 ACE
28 11.17 VEGFA SERPINE1 IL6 F3 EDN1 CXCL8
29 11.13 VEGFA SERPINE1 EDN1 ANGPT2
30 10.88 KDR IL6 CXCL8 CXCL12 CD40LG CCL2

GO Terms for Retinal Vein Occlusion

Cellular components related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VEGFA SERPINF1 SERPINE1 SERPINC1 LOXL1 KDR
2 collagen-containing extracellular matrix GO:0062023 9.76 SERPINF1 SERPINE1 SERPINC1 LOXL1 F3 F2
3 extracellular space GO:0005615 9.55 VEGFA SERPINF1 SERPINE1 SERPINC1 LOXL1 IL6
4 platelet alpha granule lumen GO:0031093 9.43 VEGFA SERPINE1 F5

Biological processes related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.04 IL6 CXCL8 CXCL12 CD40LG CCL2
2 positive regulation of cell proliferation GO:0008284 10.04 VEGFA KDR IL6 F2 EDN1 CXCL12
3 cytokine-mediated signaling pathway GO:0019221 9.96 VEGFA IL6 F3 CXCL8 CCL2
4 cellular protein metabolic process GO:0044267 9.93 SERPINC1 IL6 F5 F2
5 negative regulation of gene expression GO:0010629 9.93 VEGFA SERPINF1 KDR EDN1 ACE
6 positive regulation of cell migration GO:0030335 9.92 VEGFA KDR F3 EDN1 CXCL12
7 blood coagulation GO:0007596 9.91 VKORC1 SERPINC1 F5 F3 F2
8 cellular response to lipopolysaccharide GO:0071222 9.9 SERPINE1 IL6 CXCL8 CCL2
9 regulation of cell shape GO:0008360 9.88 VEGFA KDR F2 CCL2
10 platelet degranulation GO:0002576 9.85 VEGFA SERPINE1 F5 APOH
11 chemokine-mediated signaling pathway GO:0070098 9.8 CXCL8 CXCL12 CCL2
12 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFA KDR F3 CXCL12
13 response to hypoxia GO:0001666 9.8 VEGFA MTHFR EDN1 CXCL12 ANGPT2
14 positive regulation of endothelial cell migration GO:0010595 9.78 VEGFA KDR EDN1
15 negative regulation of blood coagulation GO:0030195 9.65 SERPINE1 EDN1 APOH
16 induction of positive chemotaxis GO:0050930 9.63 VEGFA CXCL8 CXCL12
17 angiogenesis GO:0001525 9.63 VEGFA SERPINE1 KDR CXCL8 CCL2 ANGPT2
18 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.62 EDN1 APOH
19 neutrophil mediated immunity GO:0002446 9.62 IL6 ACE
20 hemostasis GO:0007599 9.62 SERPINC1 F5 F3 F2
21 positive regulation of axon extension involved in axon guidance GO:0048842 9.61 VEGFA CXCL12
22 positive regulation of blood coagulation GO:0030194 9.61 SERPINE1 F2 APOH
23 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.59 VEGFA KDR
24 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.58 VEGFA ACE
25 positive regulation of positive chemotaxis GO:0050927 9.54 VEGFA KDR F3
26 negative regulation of fibrinolysis GO:0051918 9.43 SERPINE1 F2 APOH
27 positive regulation of angiogenesis GO:0045766 9.43 VEGFA SERPINE1 KDR F3 CXCL8 ANGPT2
28 regulation of blood coagulation GO:0030193 8.92 VKORC1 SERPINC1 F2 APOH

Molecular functions related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.62 VEGFA SERPINC1 F2 APOH
2 growth factor activity GO:0008083 9.46 VEGFA IL6 F2 CXCL12
3 chemokine activity GO:0008009 9.43 CXCL8 CXCL12 CCL2
4 signaling receptor binding GO:0005102 9.43 SERPINE1 F2 EDN1 CXCL12 CCL2 ANGPT2
5 cytokine activity GO:0005125 9.17 VEGFA IL6 EDN1 CXCL8 CXCL12 CD40LG

Sources for Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....